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Abstract
Background: Rotavirus gastroenteritis (RVGE) is the most common cause of severe childhood diarrhea worldwide.
Objectives were to estimate the burden of RVGE among children less than five years old in the Middle East
(Bahrain, Iran, Iraq, Israel, Jordan, Kuwait, Oman, Qatar, Saudi Arabia, Syria, UAE, Yemen), North Africa (Algeria, Egypt,
Libya, Morocco, Tunisia) and Turkey.
Methods: A comprehensive literature search was conducted in major databases on the epidemiology and burden
of rotavirus among children less than five years old between 1999 and 2009. Data from each country was
extracted and compared.
Results: The search identified 43 studies. RVGE was identified in 16-61% of all cases of acute gastroenteritis, with a
peak in the winter. RVGE-related hospitalization rates ranged from 14% to 45%, compared to 14%-28% for non-
RVGE. Annually, RVGE caused up to 112 fatalities per 100,000 in certain countries in the region. Hospitalization costs
ranged from $1.8 to $4.6 million annually, depending on the country. The most recent literature available showed
that G1P[8] was the most prevalent genotype combination in 8 countries (range 23%-56%). G2P[4] was most
prevalent in 4 countries (26%-48%). G9P[8] and G4P[8] were also frequently detected.
Conclusions: RVGE is a common disease associated with significant morbidity, mortality, and economic burden.
Given the variety and diverse rotavirus types in the region, use of a vaccine with broad and consistent serotype
coverage would be important to help decrease the burden of RVGE in the Middle East and North Africa.
Background
Rotavirus remains the most common cause of severe
childhood diarrhea worldwide and of diarrheal mortality
in developing countries [1]. The main symptoms of
rotavirus gastroenteritis (RVGE) are fever, abdominal
pain, lethargy, diarrhea and vomiting that may lead to
hypovolemic shock and dehydration [2,3]. Severe cases
may lead to death [4]. The World Health Organization
(WHO) estimates that 527,000 children under the age of
five years die of rotavirus disease each year [5]. Children
in the poorest countries account for 82% of rotavirus
deaths [6].
Rotavirus is transmitted by the fecal-oral route [2].
Infection rates for rotavirus are highest in children under
five years of age, with 95% of children between the age of
three and five years affected [7]. There is seasonality to
rotavirus infection, with the majority of cases in tempe-
rate climates occurring in the winter months between
November and February [2,8]. Seasonality in tropical and
developing countries is less marked [7].
Three of the seven sero-groups of rotavirus identified
affect humans, known as groups A-C. The most domi-
nant, group A, causes diarrheal diseases worldwide [2].
Group A rotaviruses are classified into G and P-types,
which are determined by the two outer layer viral pro-
teins, VP7 and VP4, respectively. These two proteins eli-
cit neutralizing antibody responses and therefore,
protection from infection and disease is believed to be
type-specific [9]. Rotaviruses are ubiquitous in the ani-
mal kingdom, and therefore, interspecies transmission
and more importantly, exchange of genetic material
between animal and human strains through re-assort-
ment can lead to the emergence of novel rotavirus
strains of epidemiological significance [9].
The incidence of infection with particular group A
rotavirus serotypes and genotypes varies between
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one season to the next [10]. Globally, viruses carrying
either G1, G2, G3, G4, G9 and P[4] or P[8] are the
most common causes of rotavirus disease in humans.
G12 is also recognized as an emergent serotype, that
may become important in human disease [11].
Often, children suffering from RVGE require outpati-
ent medical care, but in the presence of dehydration,
admission to emergency or hospitalization and intrave-
nous rehydration are necessary. Each year worldwide,
rotavirus causes approximately 111 million episodes of
gastroenteritis requiring only home care, 25 million
office visits, and 2 million hospitalizations [6]. By the
age of five years, nearly every child will have an episode
of RVGE, one in five will visit a clinic, and one in 65
will be hospitalized [6]. Thus, RVGE imposes a heavy
burden, not only by incurring direct medical costs, but
also indirect costs due to productivity loss and other
expenses [3,12,13]. Currently available rotavirus vaccines
protected against severe RVGE and were well tolerated;
the implementation of immunization programs would
be expected to reduce disease burden [3].
Burden of illness data specific to the Middle East and
North Africa is limited. The purpose of this study was
to conduct a comprehensive literature review on the
burden of rotavirus acute gastroenteritis on the pediatric
population in these regions.
Methods
Literature search strategy
To identify and retrieve articles pertaining to the impact
of rotavirus infection on the pediatric population
(≤5 years, unless otherwise specified) in the Middle East
and North Africa, a comprehensive literature search was
conducted in the National Library of Medicine’s
Pubmed, the Center for Disease Control (CDC) rota-
virus global surveillance (http://www.cdc.gov/rotavirus/
global_surveillance/surveillance.htm), and the WHO
(http://www.who.int/nuvi/rotavirus/en/). The search,
limited to articles published from 1999 to 2009, covered
the Middle East (Bahrain, Iran, Iraq, Israel Jordan,
Kuwait, Oman, Qatar, Saudi Arabia, Syria, UAE,
Yemen), North Africa (Algeria, Egypt, Libya, Morocco,
T u n i s i a ) ,a sw e l la sT u r k e yf o ri t sr e g i o n a lp r o x i m i t y .
Search terms included: rotavirus, outcome*, mortality,
death, incidence, prevalence, serotype, strain, cost*, eco-
nomic*, burden, and resource use. Reviews and case stu-
dies were excluded.
Data extraction and analysis
For all studies, dates reported for data presented refer to
the date when studies were conducted, which was often
several years before the publication date.
In the case where several surveillance studies are pub-
lished for a single country, a pooled average of the pro-
portion of RVGE among cases of acute gastroenteritis
was calculated and reported. Ranges across studies were
also reported for each country. Where available, data on
infection seasonality was collected and reported, in addi-
tion to variation over time in the proportion of RVGE.
Data was extracted for each serotype. Figures for dis-
tribution of rotavirus genotype combinations were taken
from the most recent available data, except for Turkey.
For this country, data from a prospective survey from
2004-2005 [14] was used to replace a more recent publi-
cation (2005-2006 Ceyhan study [15]), due to discrepan-
cies in the serotype data reporting (combined serotyped
data in the Ceyhan study [15] adds up to 113%). Where
two studies from the same year and the same country
showed a similar serotype distribution, a weighted aver-
age across the studies was calculated to present as one
figure. All other figures were reported as originally
described in the source documents.
Mortality data included annual fatalities and mortality
rates per 100,000 population under five years of age. For
health outcomes of rotavirus acute gastroenteritis, data
was extracted on disease severity as measured by the
20-point Vesikari scoring system [16], and the severity
and proportion of patients suffering from dehydration
due to rotavirus acute gastroenteritis. The Vesikari scale
is a numerical system used to assess RVGE disease
severity, based on the duration and intensity of diarrhea
and vomiting, intensity of fever and dehydration, and
the need for treatment and hospitalization [16]. A Vesi-
kari score ≥11 is indicative of severe disease.
For healthcare resource use data, the following para-
meters were extracted for comparison across countries:
hospital admission rates, need for intravenous rehydra-
tion, and duration of hospital stay. Cost-of-illness data
included direct medical costs, out-of-pocket expendi-
tures, and indirect costs attributed to lost productivity
by parents of children suffering from RVGE. Costs are
reported in 2008 US dollars.
No statistical analyses were performed for this review.
Results
Studies included in this review
As shown in Figure 1, this literature search recovered 43
citations which contain relevant data pertaining to acute
gastroenteritis associated with rotavirus infection on the
following topics: incidence and proportion of RVGE
among cases of acute gastroenteritis (n = 37 studies),
serotype distribution (n = 25), mortality (n = 1), disease
severity and outcomes (n = 9), healthcare resource use
(n = 11), and costs (n = 2). A summary of data sources
by country is presented in Table 1.
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Data on the proportion of RVGE was available from the
following countries: Egypt [17-21], Iran [18,22-27], Iraq
[18,28], Jordan [18,29], Kuwait [30], Libya [18,31,32],
Morocco [18,33], Oman [18,34,35], Saudi Arabia
[36-40], Syria [18], Tunisia [18,41-46], Turkey
[14,15,47-50], and Yemen [18]. No studies were found
from Algeria, Bahrain, Israel, Qatar, and the United
Arab Emirates. Most studies contained data on the pro-
portion of RVGE rather than RVGE incidence. Only one
study contained incidence data [21].
Incidence
In Egypt, a population-based cohort study of children
under three years of age reported age-related incidence
of 0.61 rotavirus diarrheal episodes per person-year
between 1995 and 1996 [21]. In this cohort, age-related
incidence was highest in children aged 6 to 11 months.
Proportion and seasonality of RVGE
When looking at the most recent studies that report
data on the proportion of RVGE for children under five
years of age in Middle Eastern and North African coun-
tries, the proportion of RVGE among cases of acute
gastroenteritis ranged from 16% to 61% per year (Figure 2).
Among the countries with the lowest proportion of RVGE
(16% to 23%) were Saudi Arabia [36-40], Tunisia
[18,41-46], and Egypt [17-19,51]. Those with the highest
proportion of RVGE included Syria (61%) [18], Oman
(50%) [18,34,35], and Kuwait (44%) [30]. One study
covered the WHO Eastern Mediterranean region as a
whole, including many of the above countries (Egypt, Iran,
Iraq, Jordan, Libya, Morocco, Oman, Syria, Tunisia, and
Yemen) as well as Afghanistan and Sudan [18]. In this
study, the overall annual prevalence of RVGE among
reported episodes of gastroenteritis in children under five
years of age was 42% [18].
A number of countries reported seasonality data
including Egypt [19,21], Iran [22,23,26,27], Libya [31],
Morocco [33], Oman [34], Saudi Arabia [37], Tunisia
[42,45,46], and Turkey [14,15,49,50]. For most of these
countries, the peak season for rotaviral gastroenteritis is
in the winter from November to April. The exception to
this is Egypt where rotaviral infection peaks in July to
November [19,21].
Variation in the proportion of RVGE over time
As illustrated in Figure 3, the proportion of RVGE among
acute gastroenteritis cases appears to have increased
over time in Egypt (from 8% to 42% between 2000 and
2007) [18,19] and Iran (from 15% in 2003-2004 to 59% in
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Figure 1 Flow chart representing the selection of relevant citations.
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Page 3 of 112006-2007) [22,27]. Proportion of RVGE in Saudi Arabia
has fallen from 35% in 1995-1996 to around 12% since
2002-2003 [38,40]. Proportion of RVGE in the other
countries for which data over time was available has
remained relatively stable.
Rotavirus genotype combinations in the Middle East and
North Africa
Distribution of genotype combinations
As shown in Figure 4, G1P[8] was the most prevalent
genotype combination in eight of the 14 countries for
Table 1 Literature capture and data sources by country
Country Epidemiology Genotype combination data Morbidity and Mortality Disease Burden
Incidence Proportion RVGE Seasonality Disease severity Mortality Resource use Costs
Multicountry* [18]
† [55]
‡
Algeria [55]
Bahrain [55]
Egypt [21] [17-21] [19,21] [17,17,18,18,21,53] [19,21,51] [55] [19,51]
Iran [18,22-27] [22,23,26,27] [18,22,26] [55] [25]
Iraq [18,28] [28] [55]
Israel [52] [55] [52,57] [52]
Jordan [18,29] [18] [29] [55] [29]
Kuwait [30] [30] [55]
Libya [18,31,32] [31] [32] [55]
Morocco [18,33] [33] [18,33] [33] [55] [33]
Oman [18,34,35] [34] [18,34,35] [55] [34] [34]
Qatar [55]
Saudi Arabia [36-40] [37] [36-38] [55]
Syria [18] [55]
Tunisia [18,41-46] [42,45,46] [41,44,44,46] [42] [55]
Turkey [14,15,47-50] [14,15,49,50] [14,15,48] [15,47,50] [55] [15,47,50]
UAE [55]
Yemen [18] [18] [55]
*Where country-specific data was available within a multicountry study, it has been extracted. Therefore, the relevant reference has been added to individual
countries above.
†Egypt, Iran, Iraq, Jordan, Libya, Morocco, Oman, Syria, Tunisia, and Yemen.
‡All countries.
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Figure 2 Mean overall proportion of rotavirus gastroenteritis (% of reported acute gastroenteritis cases) by country.
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Page 4 of 11which recent data was available (Israel [52], Iraq [28],
Kuwait [30], Libya [32], Morocco [33], Saudi Arabia
[37], Tunisia [44], and Turkey [14]), with a proportion
ranging from 23% to 56% of all genotyped samples. G2P
[4] was the most prevalent genotype combination in
four countries (Egypt [17,18], Jordan [18], Oman
[18,34], and Yemen [18]; range 26%-48%), and was
detected in every country except Tunisia. G9P[8] was
detected in 10 of the 14 countries for which there was
literature available (Egypt [17,18,53], Israel [52], Iraq
[28], Kuwait [30], Libya [32], Morocco [18,33], Oman
[35], Saudi Arabia [36-38], Tunisia [41,44], and Turkey
[14,15,48]), and was highly prevalent in Morocco [33]
and Libya [32] (31% and 34% of genotype combinations,
respectively). G4P[8] was most prevalent in Iran [18]
(27% of genotyped samples, respectively), and was pre-
sent in Iraq [28], Kuwait [30], Tunisia [44,46], Turkey
[14], and Yemen [18] (proportion range 2%-18%).
Other genotype combinations were also present in
multiple countries as follows. G1P[4] (Egypt, Israel, Jor-
dan, Kuwait, Oman, Tunisia, Turkey and Yemen; pro-
portion range 0.2%-14%); G1P[6] (Egypt, Iraq, Jordan,
Libya, Morocco, Pakistan, Turkey, and Tunisia; range
1%-14%); G3P[8] (Israel, Iran, Jordan, Kuwait, Saudi
Arabia and Tunisia). Rarer genotype combinations, each
present in six countries or fewer, accounted for 10% or
less of the total genotype combinations (Table 2). Mixed
genotype combinations, including G1G2 and G1G4,
were detected in most countries (2%-25% of the total
rotavirus positive samples). Non-typable and partially
typed serotypes accounted for a significant proportion
of serotype samples, ranging between 5% and 20% for
non-typable, and 5% to 19% for partially typable
samples.
Evolution of genotype combinations over time
Studies from six countries reported distribution over
time of fully genotyped samples from children ≤5y e a r s
of age: Egypt [17,18,21], Iran [18,22,26], Oman
[18,34,35], Saudi Arabia [36,38], Tunisia [44], and Tur-
key [14,48] (Figure 5). In Egypt, the proportion of G2P
[4] fell, and G1P[8] increased between 1995-1996 and
2006-2008 [17,18,21]. Over the same time frame, G9P[8]
was detected (7%). In Iran, G1P[8] proportion declined,
and G4P[8] became the most prevalent genotype combi-
nation in 2006-2008 [18,22,26]. In Saudi Arabia, there
was a decrease in both G1P[8] and G9P[8] (16% to
11%), while G2P[4] increased from 2002-2003 to 2004-
2005 [36,38]. In Tunisia, G1P[8] and G1P[6] were
replaced by a variety of genotype combinations including
G1P[4], G9P[8], and G3P[8] [44]. Finally in Turkey, the
predominant genotype combination G1P[8] increased in
proportion, while G4P[8] declined [14,15,48].
Two studies, both from Tunisia, covered the emer-
gence of new serotypes in North Africa [41,46]. The ear-
lier study by Trabelsi et al, described the emergence of a
reassorted strain G1P[4] in the Sousse region in the
1998-1999 season. G1, G2, and G4 strains were preva-
lent at this time, with no detection of G3 or G9 [46].
The second, a prospective study of five hospitals in East-
ern-Central Tunisia described the emergence of G9
serotypes during 2003-2005, further characterized as
G9P[8] [41].
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Figure 3 Proportion of rotavirus gastroenteritis (% of reported acute gastroenteritis cases) by country and year of study. Dates refer to
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Table 2 Rare genotype combinations from the Middle East and North Africa by country (recent studies)
Egypt Israel Iran Iraq Jordan Kuwait Morocco Oman Saudi
Arabia
Tunisia Turkey Yemen
Serotype 2006-
08
2007-
08
2006-
08
2006 2006-
08
2005-
06
2006-07 2006-
08
2004-05 2004 2004-
05
2006-
08
no f
countries
G2P[8] 5.96% 2.80% ––– 1.30% 0.70% ––– 1.60% 2.20% 6
G4P[6] ––– 1.50% – 1.30% –– – 3.80% –– 4
G2P[6] 1.88% –– – 1.80% – 9% ––– – – 3
G3P[4] – 7.40% – – ––– – 3.80% 1.60% – 3
G12P[8] – 4.60% – – ––– 4% 1.90% – 3
G9P[4] – 0.90% –– – – 2.9% –– 1.60% – 3
G9P[6] ––– 1.50% – ––– – – 3.10% – 2
G12P[6] 6.96% –– –– – – – ––– 1
G3P[9] –– 0.78% – ––– – – – – 1
G2P[10] – – ––– – –1.3% –– – – 1
G1P[10] – – ––– – –1.2% –– – – 1
G3P[6] – – ––– – – – – 1.90% –– 1
G4P[4] – – ––– – – – – 1.90% –– 1
G8P[4] – – ––– – – – – – 1.50% – 1
G1P[11] – – ––– – – – – – – 2.20% 1
G9P[11] – – ––– – – – – – – 2.20% 1
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Disease severity
Data pertaining to disease severity and dehydration due
to RVGE in the Middle East and North Africa was avail-
able from the following countries only: Egypt [19,21,51],
Jordan [29], Morocco [33], Tunisia [42], and Turkey
[15,47,50]. Dehydration was a common health outcome
reported by all studies, affecting around 50% of children
with RVGE [19,21,42,50,51]. In 3% to 25% of cases,
dehydration was classified as severe [15,19,21,42,54].
Furthermore, disease severity, measured on the Vesikari
s c a l e ,w a se x p l o r e db yo n es t u d yf r o mM o r o c c o[ 3 3 ]
and three Turkish [15,47,50] studies. In Morocco, a pro-
spective surveillance study of 345 hospitalized children
with rotavirus estimated a median Vesikari score of 14
[33]; this score was significantly higher than the one
obtained among children with non-RVGE (P = 0.03). In
Turkey, prospective hospital-based studies showed that
between 37% and 90% of children with rotavirus had
severe disease on the Vesikari scale [15,47,50].
Mortality
Information on mortality due to RVGE in the Middle
East and North Africa was limited to the WHO report
on death estimates from all countries of interest [55] In
the countries covered in this study, fatalities due to
RVGE ranged from a low of <10 per year (Bahrain,
Israel, Kuwait, and Qatar) to a high of 4,723 per year
(Iraq). This translates into annual mortality rates of 0 to
112 per 100,000 infants under five years of age (Figure 6)
[55]. When the overall pediatric population below five
years of age was considered, the average mortality rate
from the 20 countries was estimated at 39 per 100,000
per year (17,766 rotavirus deaths per 45,437,000 children
<5 years of age–estimate based on demographic indica-
tors from UNICEF [56]).
Healthcare resource use
Overall, 11 studies reported healthcare resource use data
from Egypt [19,51], Iran [25], Israel [52,57], Jordan [29],
Morocco [33], Oman [34], and Turkey [15,47,50].
Hospital admissions
In Egypt, two hospital-based studies reported hospital
admission rates due to RVGE among young children.
This rate varied between 14% among children present-
ing with diarrhea at a hospital in Southern Egypt [51],
and 45% among those presenting at two government
referral hospitals in the Nile River Delta [19]. Hospitali-
zation rates were 39% among toddlers with RVGE
(<2 years) in Iran [25], and 31% among children younger
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Page 7 of 11than five years of age in Turkey [50]. Interestingly, the
Turkish prospective survey, involving 920 patients
admitted for acute gastroenteritis, found that rotavirus-
positive gastroenteritis caused a significantly higher rate
of hospital admissions versus non-RVGE (31% vs 14%
non-RVGE; P < 0.01) [50]. In Oman, a prospective hos-
pital-based surveillance study estimated that, by age five
years, one in 16 children will require hospitalization due
to rotavirus [34].
Intravenous rehydration
At least 90% of hospitalized children with RVGE
required intravenous rehydration in Morocco [33],
Oman [34], and Turkey [15,47]. This figure was 63% in
a prospective survey from Jordan [29], and 67% among
children aged <18 months in Israel [57].
Duration of hospital stay
Data from three countries indicated that RVGE among
young children required hospitalization of at least three
days, as reported in a prospective surveillance study
from Oman (median: 3 days) [34], and a population-
based cohort study in Israel (mean: 3.0 ± 2.9 days) [52].
In Turkey, the mean hospital duration was longer for
RVGE than non-rotavirus disease (5.5 ± 5.1 days vs 3.3
± 3.1 days non-rotavirus) [50]. A prospective study of
three pediatric departments in Israel reported that hos-
pital stay was longer among younger children with
nosocomial RVGE (3.5 vs 2.1 days for children <6
months old and those >26-48 months, respectively) [57].
In this study, hospital duration was 3.5 and 2.1 days for
children <6 months and those between 36 and 48
months, respectively [57].
Economic burden associated with RVGE
Cost of illness data was limited to studies from Israel
[52] and Oman [34]. In Israel, the total cost of hospitali-
zation (direct medical costs) was estimated at 2008 US
$1,117 per patient for an average of three hospital days,
for a total of $4.59 million per year for all Israel patients
[52]. One episode of RVGE was estimated to incur
out-of-pocket expenses of $281, for a national annual
estimate of $1.15 million paid by parents (extra diapers,
transportation, over-the-counter medications, special
diet, medical consultations), and caused productivity
loss of four to six days of work at a cost of $476 per
patient hospitalized, for a national annual estimate of
$1.95 million for indirect costs [52]. In Oman, Al
Awaidy et al (2009) [34] estimated the direct cost for
three days of hospitalization at $539 per event, or $1.80
million per year. Out-of-pocket and indirect costs were
not reported in this study.
Discussion
Based on data collected from 44 studies in the Middle
East and North Africa, this analysis shows that rotavirus
imposes a heavy burden among children less than five
years of age. Overall, the annual proportion of RVGE
among reported episodes of pediatric gastroenteritis in
t h eM i d d l eE a s ta n dN o r t hA f r i c ar e g i o nw a s4 2 %[ 1 8 ] .
This figure is similar to a published estimate of the pro-
portion of RVGE (43%) from a prospective multicountry
study in Western Europe [58], further emphasizing the
ubiquitous nature of the disease [7]. However, when
Middle Eastern and North African countries were com-
pared to each other, large variations in proportion of
RVGE estimates were observed, with a low of 16%-23%
reported in Saudi Arabia, Tunisia, and Egypt, and a high
of 44%-61% in Syria, Oman, and Kuwait. These varia-
tions may reflect actual differences in RVGE proportion
but may also be related to variations in study design,
which limit comparability across countries.
A considerable amount of information on serotype
distribution in the countries of interest was retrieved,
highlighting the predominance of G1P[8] and G2P[4].
These genotype combinations are also predominant in
Western Europe [59]. In the present study, the propor-
tion of non-typable and partially typable genotype com-
binations varied widely across countries [22,26,36,37].
The reason for this discrepancy is not clear, although it
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Page 8 of 11might be due to differences in study design and setting,
or to laboratory practice differences from country to
country.
Several studies assessed the evolution of serotype
distribution over time and the emergence of new rotavirus
strains in the Middle East and North Africa. All of these
prevalent (G2P[4] [36,38], G4P[8] [18,22,26], G3P[8] [44])
and emerging (G9P[8] [17,18,21,41]; G1P[4] [46]) sero-
types belong to the most commonly described strains of
rotavirus that are responsible for gastroenteritis disease in
humans [10]. Interestingly, G12, a recently emerging sero-
type detected in Europe, Asia, and the Americas
[11,60,61], has not been reported in any of the studies cap-
tured in this review.
A wide inter-country variation was noticed in mortal-
ity rates due to RVGE, with the highest rates reported
in Iraq and Yemen compared to less than one fatality in
Bahrain, Israel, and Kuwait (Figure 6). Based on demo-
graphic indicators from UNICEF, the average annual
mortality rate in the region was estimated at 39 per
100,000. This rate is considerably higher than in Europe,
where rotavirus rarely results in child death (mortality
rate below 10 per 100,000) [55]. These inter-country
and inter-region variations are in agreement with
previous reports showing that children in the poorest
countries account for 82% of rotavirus deaths [6].
Because of data limitations, it cannot be concluded from
this study whether differences in mortality rates are due
to variations in clinical management of the disease.
The hospital admission rates and the use of intrave-
nous rehydration were similar to European figures
reported in the multicentre RVGE Epidemiology and
Viral types in Europe Accounting for Losses in public
health and society (REVEAL) study [62]. As well, the
higher rates of hospitalization and higher disease sever-
ity for rotavirus versus non-rotavirus acute gastroenteri-
tis reported in this review were in line with data
reported in Western Europe [63].
Rotavirus cost information was very limited in the
Middle East and North Africa. Per episode of RVGE,
direct medical costs in the Middle East and North
Africa ($467 to $1,117) were lower than those reported
in Western Europe (ranging from 2008 US $1,949 in the
UK to $2,398 in Sweden) [62].
Study limitations are worth mentioning. Most pub-
lished articles retrieved in this study reported serotype
and epidemiological data; information on the burden of
RVGE in terms of mortality, morbidity, and economic
burden was limited. This in term restricted the evalua-
tion of the global burden for the region. Most recent
available data was considered to describe and compare
serotype distribution across countries; however, the only
available data was not necessarily recent and did not
correspond to the same time frame in all countries.
For example, the only serotype information for Libya
was published in 2000 [32], therefore conclusions on
serotype distribution for this country may have changed,
and comparison with 2008 data from other countries
would be limited. Moreover, due to data limitations, a
clear relationship between certain rotavirus genotypes
and disease severity could not be established. Finally,
variations in study setting and design may affect com-
parability of data.
Conclusions
RVGE is a common disease associated with significant
morbidity, mortality and costs in the Middle East and
North Africa. The results of this study may be useful as
background information to the planning and implemen-
tation of efficient vaccination programs. Given the vari-
ety and diverse rotavirus types in the region, a vaccine
with broad and consistent serotype coverage would be
important to help decrease the burden of RVGE in the
Middle East and North Africa.
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